Saurabh Saha MD, PhD

Dr. Saha is a physician-scientist, pharmaceutical executive, and biotech entrepreneur dedicated to discovering and developing novel cancer medicines. He is notable for leading the development and demonstrating human effectiveness of two first-in-class cancer drugs, an ERK kinase inhibitor, and bacteriolytic immunotherapy.

Dr. Saha is the Senior Vice President of R&D and Global Head of Translational Medicine for all disease areas at Bristol-Myers Squibb. He is also the Site Head for Bristol-Myers Squibb R&D headquarters in Cambridge MA. Dr. Saha was a Venture Partner at Atlas, a venture capital firm in Cambridge MA, and most recently served as President and Chief Executive Officer at Delinia. In 2017, he led the acquisition of Delinia by Celgene for $775 million.

Previously he was Chief Medical Officer of Synlogic and a member on the Board of Directors of BioMed Valley Discoveries, a biotech company he played a pivotal role to launch as Chief Scientific Officer and subsequently serve as President for over 6 years. In 2005, Dr. Saha was recruited from McKinsey & Company to become the global head of the New Indications Discovery Unit at Novartis Pharmaceuticals. His work on developing new medicines has been featured in TIME Magazine, the Times, FOX, The Wall Street Journal and The Economist.